CN1603834A - System and method for processing related laboratory tests and results - Google Patents
System and method for processing related laboratory tests and results Download PDFInfo
- Publication number
- CN1603834A CN1603834A CNA2004100301359A CN200410030135A CN1603834A CN 1603834 A CN1603834 A CN 1603834A CN A2004100301359 A CNA2004100301359 A CN A2004100301359A CN 200410030135 A CN200410030135 A CN 200410030135A CN 1603834 A CN1603834 A CN 1603834A
- Authority
- CN
- China
- Prior art keywords
- results
- user
- expected
- test result
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009533 lab test Methods 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims abstract description 18
- 238000012545 processing Methods 0.000 title claims description 18
- 238000012360 testing method Methods 0.000 claims abstract description 188
- 238000010200 validation analysis Methods 0.000 claims abstract description 47
- 238000012795 verification Methods 0.000 claims description 75
- 230000004044 response Effects 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 244000045947 parasite Species 0.000 claims description 3
- 238000013475 authorization Methods 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims 6
- 230000000977 initiatory effect Effects 0.000 claims 5
- 238000013474 audit trail Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000012552 review Methods 0.000 abstract description 29
- 238000009640 blood culture Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 11
- 238000007689 inspection Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 9
- 238000010876 biochemical test Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002906 microbiologic effect Effects 0.000 description 5
- 238000012790 confirmation Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000005416 organic matter Substances 0.000 description 3
- 238000007781 pre-processing Methods 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- DXMQZKIEVHKNTN-UHFFFAOYSA-N 2-[carbamimidoyl(ethyl)amino]acetic acid Chemical compound CCN(C(N)=N)CC(O)=O DXMQZKIEVHKNTN-UHFFFAOYSA-N 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Images
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medical Treatment And Welfare Office Work (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
这是由D.Brumbach等人于2003年3月19日提交的临时申请序号60/455,934的非临时申请。This is a non-provisional application of Provisional Application Serial No. 60/455,934 filed March 19, 2003 by D. Brumbach et al.
技术领域technical field
本发明涉及实验室检验(test)且更具体地涉及在微生物学检验实验室里在贯穿临床培养物的检验生命周期的始终验证(validate)检验结果。The present invention relates to laboratory tests and more particularly to the consistent validation of test results throughout the test life cycle of clinical cultures in microbiological testing laboratories.
背景技术Background technique
临床实验室被赋予这样的任务,即执行对临床培养物的检验以标识可正在引起患者内感染的有机体。在正常操作期间,微生物学实验室部门接收由医生所收集的各种患者试样。微生物学技师将试样平涂在培养基上且孵育培养基。被平涂的试样在本技术中通常被称为“临床培养物”。经过一定的时间,有机物在临床培养物上生长。微生物学技师的责任是从临床培养物中识别可正在引起患者内感染的任何有机物(例如,细菌,真菌(fungus),微细菌,寄生物,病毒)并且提供技师所知的可适用于治疗可能的感染源的任何抗菌信息。Clinical laboratories are tasked with performing tests on clinical cultures to identify organisms that may be causing infections in patients. During normal operation, the microbiology laboratory department receives various patient samples collected by physicians. The microbiologist spreads the sample flat on the medium and incubates the medium. The flat-coated samples are commonly referred to in the art as "clinical cultures". After a certain period of time, organoids are grown on clinical cultures. It is the responsibility of the microbiology technologist to identify from clinical cultures any organisms (eg, bacteria, fungus, microbacteria, parasites, viruses) that may be causing an infection in the patient and to provide information that is applicable to therapeutic possibilities to the knowledge of the technologist. any antimicrobial information on the source of infection.
正如传统地,实验室技师在通常被称为临床培养物“检验生命周期”的数小时、天或周期间分析临床培养物。贯穿培养物的“检验生命周期”的始终,当生物化学检验被执行时,技师周期性地将单个的检验结果输入到实验室系统。当这些单个的检验结果出现时其被典型地发布给技师。基于从前的结果,在生命周期较后阶段所输入的结果应该具有预期的后果。作为一个实例,如果较早被执行的检验,如GramStain(革兰氏染色剂)检验被报告为许多Gram Negative Rods(革兰氏阴性棒),则在较后被执行的检验,如有机物ID检验中见识广的技师应该预料到作为较后的检验结果的Gram Negative Organism(革兰氏阴性有机体)。As traditionally, laboratory technicians analyze clinical cultures during what is often referred to as the "assay life cycle" of clinical cultures. Throughout the "assay life cycle" of a culture, as biochemical assays are performed, technicians periodically enter individual assay results into laboratory systems. These individual test results are typically released to technicians as they occur. Results entered in later stages of the life cycle should have expected consequences based on previous results. As an example, if a test performed earlier, such as the GramStain test, is reported as many Gram Negative Rods, then a test performed later, such as the Organism ID test A knowledgeable technician should expect Gram Negative Organism as a final test result.
技师义不容辞地是当输入较后的结果时将较早检验的结果考虑进去,这样不一致或错误的结果并不被发布给医生用于复查。It is incumbent on the technician to take the results of the earlier tests into account when entering the later results so that inconsistent or erroneous results are not released to the physician for review.
这个过程的缺点是其的不可预测性和不一致性。具体地,技师区分预期和非预期结果的能力部分地取决于技师所获取和所记忆的可随技师到技师而变化的知识,他就参考图,手册以及监督复查的程序的能力。The downside of this process is its unpredictability and inconsistency. Specifically, the technician's ability to distinguish expected from unanticipated results depends in part on the technician's acquired and retained knowledge, which may vary from technician to technician, on his ability to refer to diagrams, manuals, and procedures for supervisory review.
所述过程的另一缺点是培养物试样的验证是在培养物被定案之后(即在检验生命周期的结束时)而被执行的。在多数情况下这太迟了,因为任何非预期的中间结果当其发生时便已经被发布给医生用于复查。相反验证应该优选地在贯穿培养物的检验生命周期始终通过连续地监视检验结果且当其出现时将其与其它培养结果比较而被执行,而不象传统那样在最后阶段。Another disadvantage of the described process is that the validation of the culture samples is performed after the cultures are finalized, ie at the end of the assay life cycle. In most cases this is too late, as any unexpected intermediate results would have already been issued to physicians for review by the time they occurred. Instead verification should preferably be performed throughout the assay life cycle of the culture by continuously monitoring the assay results and comparing them with other culture results as they arise, and not at the final stage as is conventional.
另一缺点是没有消息能力,以用于当非预期结果出现时通知技师要采取什么附加步骤。Another disadvantage is that there is no messaging capability to inform the technician what additional steps to take when unexpected results occur.
另一缺点是在验证期间数量并不被加以考虑,由此使验证不精确。Another disadvantage is that the quantity is not taken into account during verification, thus making the verification imprecise.
不存在克服了上述所提到缺点的用于处理与实验室检验和结果有关信息的已有系统。There is no existing system for processing information related to laboratory tests and results that overcomes the above mentioned disadvantages.
发明内容Contents of the invention
本发明强调对得到改善的微生物学验证系统的需求。在临床微生物学实验室在培养物的“检验生命周期”期间,在数小时、天或周期间若干结果被输入且被发布。本发明通过提供这样的技术对这个过程加以改善,当输入较后被执行的检验的结果时所述技术考虑较早被执行的检验的结果,以便于不一致性或错误的结果并不被发布给技师用于复查。The present invention highlights the need for improved microbiological validation systems. During the "assay life cycle" of a culture in a clinical microbiology laboratory, several results are entered and issued over hours, days or weeks. The present invention improves on this process by providing a technique that takes into account the results of tests performed earlier when entering the results of tests performed later so that inconsistent or erroneous results are not issued to Technician for review.
根据本发明的一个方面,一种用于处理有关实验室检验和结果的方法包括:接口处理器,其接收用以标识患者的实验室检验结果和实验室检验的预期结果的由用户所输入的数据。验证处理器将实验室检验结果与预期的检验结果进行比较并且在其中实验室检验结果未能与预期的检验结果匹配的情况下标识失败条件。结果处理器向用户产生警告消息,从而通知用户失败条件。According to one aspect of the present invention, a method for processing related laboratory tests and results includes: an interface processor that receives user-input data. The verification processor compares the laboratory test result to the expected test result and identifies a failure condition where the laboratory test result fails to match the expected test result. The result processor generates a warning message to the user, thereby notifying the user of the failure condition.
附图说明Description of drawings
现在参考附图,其中贯穿始终相似的参考号表示对应的部件,其中:Referring now to the drawings, wherein like reference numerals designate corresponding parts throughout, wherein:
图1示例一个用于处理有关实验室检验/结果信息的微生物学验证系统的实施例;Figure 1 illustrates an embodiment of a microbiological verification system for processing information about laboratory tests/results;
图2是示范性显示图像窗口,其示例用于构建微验证定义的微验证用户定义样板(UDT);Figure 2 is an exemplary display image window illustrating a micro-verification user-defined template (UDT) for building a micro-verification definition;
图3是包括在图2的UDT上端部分中的那些微验证参数的示范性清单;以及Figure 3 is an exemplary list of those micro-authentication parameters included in the upper part of the UDT of Figure 2; and
图4-10是根据本发明方面的各种用户接口屏的计算机显示图像窗口。4-10 are computer display image windows of various user interface screens in accordance with aspects of the present invention.
具体实施方式Detailed ways
本发明系统适合于使用在药学和放射学信息系统且使用户能够定义简单或复杂的结果验证过程和消息。所述系统具有在医院实验室设置的特定应用,从而使能对培养物高效且准确的分析。培养物的分析可包括报告各种微生物类型,其可包括细菌、真菌(fungi)、寄生物和病毒。就这个上下文本发明被加以说明。在此所使用的处理器是用于执行任务的一设备和/或一机器可读取的指令集合。处理器包括硬件、固件及/或软件中的任何一个或组合。处理器通过操纵、分析、修改、转换、传输由可执行程序、信息设备所使用的信息,并且/或将所述信息发送到输出设备而作用于信息。处理器可使用控制器的能力。The system of the present invention is suitable for use in pharmaceutical and radiology information systems and enables users to define simple or complex result verification procedures and messages. The system has particular application in hospital laboratory settings, enabling efficient and accurate analysis of cultures. Analysis of cultures may include reporting of various microbial types, which may include bacteria, fungi, parasites, and viruses. It is in this context that the invention is described. A processor as used herein is a device and/or a set of machine-readable instructions for performing tasks. A processor includes any one or combination of hardware, firmware, and/or software. A processor acts on information by manipulating, analyzing, modifying, converting, transmitting the information for use by executable programs, an information device, and/or sending the information to an output device. The processor may use the capabilities of the controller.
本发明系统提供若干超出现有技术系统的具体优点,其包括贯穿培养物的生命周期始终通过连续地监视检验结果且当它们出现时与从前所获得的检验结果进行比较而执行对检验培养物的验证。由本发明所提供的另一优点是贯穿培养物的生命周期始终监视被输入的检验结果的能力。当定义预期的结果并且在将非预期的结果发布给技师用于复查之前向用户警告时,本发明还有利地考虑具体的数量。另一优点允许用户定义谁可以忽略(override)验证失败并且在相关方面,允许直接从验证失败窗口输入忽略注释。就具体的消息传递,本发明向用户提供定义用户消息并且允许用户定制系统以向其它人提供提示的能力。本发明还包括失败管理报告,其列出已经被实验室技师所忽略的那些检验。就有关预期的和实际的检验结果,本发明提供一验证失败窗口,其既显示预期的检验结果值又显示引起验证失败的实际检验结果,并且允许用户来定义或构建所组成预期结果的内容,而不是定义预期结果的例外。The system of the present invention offers several specific advantages over prior art systems, which include that the testing of cultures is performed by continuously monitoring test results throughout the life cycle of the culture and comparing them as they arise with previously obtained test results. verify. Another advantage provided by the present invention is the ability to monitor input test results throughout the life cycle of the culture. The invention also advantageously takes into account specific quantities when defining expected results and warning the user before releasing unexpected results to a technician for review. Another advantage allows users to define who can override validation failures and, in a related aspect, allows input of override comments directly from the validation failure window. In terms of messaging specifically, the present invention provides users with the ability to define user messages and allow users to customize the system to provide reminders to others. The present invention also includes a failure management report listing those tests that have been ignored by the laboratory technician. With regard to expected and actual test results, the present invention provides a verification failure window that displays both the expected test result value and the actual test result that caused the verification failure, and allows the user to define or construct the content of the composed expected result, Instead of defining exceptions for expected results.
在此所说明的被公开元素可由硬件部分(例如分立的电子电路)、软件部分(例如计算机编程)或任何其组合所组成。根据本发明的所述系统可被实施在运行UNIX,Windows NT,Windows 2000或WindowsXP的任何适合计算机上。显然地,当技术变化时,在未来其它计算机和/或操作系统可是优选的。在此所公开的系统可以由使用市场上可获得的研制工具的编程器加以实施。The disclosed elements described herein may consist of hardware components (eg, discrete electronic circuits), software components (eg, computer programming), or any combination thereof. The system according to the invention can be implemented on any suitable computer running UNIX, Windows NT, Windows 2000 or Windows XP. Obviously, other computers and/or operating systems may be preferred in the future as technology changes. The systems disclosed herein can be implemented by a programmer using commercially available development tools.
本技术领域中普通的一个技术人员可以意识到在本发明实施例的图中所示例的显示图像窗口表示一个可能的设置,且其它设置可被使用,所述其它设置可包括代替图中所示例的一个图像窗口的几个图像窗口,或相反地表示几个图像窗口,或不同图像窗口设置的一个图像窗口。One of ordinary skill in the art will recognize that the display image window illustrated in the figures of the embodiments of the present invention represents one possible setup, and that other setups may be used, including Several image windows of one image window, or conversely several image windows, or one image window of different image window settings.
就在临床微生物学实验室内的检验培养物的非限制性上下文中,微生物学验证系统被加以说明。The microbiology validation system is described in the non-limiting context of testing cultures within a clinical microbiology laboratory.
参考图1本发明可被更加完全地加以理解,所述图1示例根据本发明一个实施侧的微生物学验证系统100。所述微生物学验证系统100包括,例如接口处理器2、验证处理器4、结果处理器6和微验证定义数据库8。所述微验证定义数据库8存储对需要被验证的那些实验室检验的预期检验结果加以定义的微验证定义,下面将要对此加以说明。The present invention may be more fully understood with reference to FIG. 1 , which illustrates a microbiological verification system 100 according to one implementation of the present invention. The microbiological validation system 100 includes, for example, an
在示范性实施例中,微生物学验证系统100由集成在外部计算机系统如医院实验室信息系统(LIS)内的一个或多个软件模块所组成。In the exemplary embodiment, microbiology validation system 100 is comprised of one or more software modules integrated within an external computer system, such as a hospital laboratory information system (LIS).
本发明以两阶段,预配置阶段和操作阶段操作。在预配置阶段,用户就有关即将执行临床培养的多个检验当中的哪些检验要求验证做出确定。如在此所定义,验证涉及基于用户所供给的预先定义的预期结果寻找非预期的检验结果。对于由用户要求验证所标识的那些检验,用户建立对预期结果加以定义的一个或多个微验证定义。一旦被建立,微验证定义被存储在微验证定义数据库8内,用于在操作阶段的随后调用,用于与实际检验结果相比较以确定要求验证的检验的有效性或无效性。所述过程的两个阶段,预配置和处理被更详细地说明如下:The present invention operates in two phases, a preconfiguration phase and an operational phase. In the pre-configuration phase, the user makes a determination as to which of the plurality of tests to be performed for clinical training requires validation. As defined herein, verification involves finding unexpected inspection results based on predefined expected results supplied by the user. For those tests identified by user-required validations, the user creates one or more micro-validation definitions that define expected results. Once established, the micro-verification definitions are stored within the
在预配置阶段,用户(顾客)首先决定要执行特定临床培养的那些实验室检验当中的哪些检验需要验证。在随后示例性实例中,参考血的临床培养物。在血临床培养物的具体情况下,典型地对要求验证的血培养物试样所执行的一个检验是GRAM检验。为了验证GRAM检验,用户完成图2的用户定义样板(UDT)200,其包括数据如:预期的GRAM检验结果,多个预先条件,以及一个或多个进一步被定义的检验及其预期的结果,其中考虑到较早被执行的GRAM检验及其预期结果,进一步被定义的检验的预期结果由用户供给。In the pre-configuration phase, the user (customer) first decides which of those laboratory tests to perform a particular clinical culture require validation. In the illustrative examples that follow, reference is made to clinical cultures of blood. In the specific case of blood clinical cultures, one test typically performed on blood culture samples requiring validation is the GRAM test. In order to verify the GRAM test, the user completes the user-defined template (UDT) 200 of Figure 2, which includes data such as: expected GRAM test results, a number of preconditions, and one or more further defined tests and their expected results, The expected results of the further defined tests are supplied by the user, taking into account the earlier performed GRAM tests and their expected results.
通过完成一个或多个用户定义的样板(UDT),如图2中所示的示范性UDT,用户对要求验证的由用户标识的检验的预期结果加以定义。By completing one or more user-defined templates (UDTs), such as the exemplary UDT shown in FIG. 2, the user defines the expected results of the user-identified tests that require verification.
图2是示例UDT样板200的一个实施例的示范性显示图像窗口。UDT 200样板一旦由用户完成,便被作为要求验证的特定检验的预期结果的微验证定义被存储。如由用户所决定,微验证定义是针对要求验证的那些检验而建立的。FIG. 2 is an exemplary display image window of one embodiment of an
如上所陈述,针对要被验证的检验的微验证定义的建立要求用户标识要被验证的检验连同其预期结果,供给包括预先条件的数据并且考虑到要被验证的检验标识任何进一步的检验及其相应的预期结果。就有关任何进一步的检验,用户具有要求或不要求实际检验结果与预期检验结果匹配的选项。通过核对或不核对“Req?”项目框(entry box)238提供这个选项,所述项目框与在预配置期间标识UDT 200上进一步被定义的检验的行项目(line entry)相联系。As stated above, the establishment of a micro-verification definition for a test to be validated requires the user to identify the test to be validated together with its expected results, supply data including preconditions and allow for the test to be validated to identify any further tests and their the corresponding expected result. For any further inspection, the user has the option of requiring or not requiring that the actual inspection result match the expected inspection result. This option is provided by checking or unchecking "Req?"
UDT200的预先条件的一个实例是示于UDT 200上端部分中的“Incubation Time(孵育时间)”域230。在本实例中,用户已经输入值“1”,其表示“Incubation Time”域的1天。用户已经确定用于验证“GRAM”检验208的必要预先条件是等于或大于一天的孵育时间。An example of a precondition for
确定是否孵育时间预先条件被满足由系统100执行如下。验证处理器4被配置成核对检验结果被观察的当前日期及培养物的起始日期,以确定是否孵育时间是至少一天。如果孵育时间被确定为小于一天,则预先条件未得到满足且“GRAM”检验208的微验证不被执行。Determining whether incubation time preconditions are met is performed by system 100 as follows. The
在完成要被验证的特定检验的UDT 200时,由用户所提供的用来填写UDT样板200的微验证参数作为单个记录被存储在微验证数据库8中。所述记录由各种预先条件参数值和进一步被定义的检验及其相联系的预期值组成。微验证记录随后在执行检验验证的处理阶段期间的各种时间里被调用。Upon completion of the
图2的示范性UDT 200被示出被分成顶端部分202和底端部分204。顶端部分202包括如检验说明域,即标识要被验证的实验室检验的“Test”208,执行机构“Perf Instn”210,“result”212,组织团体优先权(“Org Grp Prio”)214,激活(“Active”)216,“CultureTest”218,“Source”220,验证说明(“Validation Desc。”)222,验证失败消息(“Validation Fail Msg”)224,“Validation Severity”(“验证严重程度”)226,所要求的忽略注释(“Override Cmnt Req?”)228,及“Incubation Time”230等域。从上面提到的域当中,定义预先条件的域包括图2中的域208、212、214、216、218、220和230。The
UDT 200的底端部分204包括若干项目行232a-h,为了验证或作废要求验证的检验(例如GRAM检验208)的目的,其用于允许用户定义进一步的实验室检验234及其相联系的预期检验结果236。The
当“Req?”项目框238被核对时,其要求当执行验证时进一步的实验室检验,例如ORG ID 234要被考虑为确认检验。在其中两个或多个进一步的实验室检验234被用作为UDT 200的底端部分204的确认检验情况下,每当至少一个确认检验的实际结果未能与其预期结果相匹配时,则失败条件发生。When the "Req?"
图3的表1说明了被示例于图2中UDT 200的顶端部分202的微验证参数。表1的第一列30标识各种微验证参数208-238。第二列32提供对第一列的微验证参数208-238的简洁说明。例如,示出针对微验证参数“validation severity”226,当非预期的检验结果即“INFO”,“WARN”或“FAIL”出现时,用户具有选择要被显示的三个消息之一的选项。所述选择可针对要被执行的不同微验证检验而不同。第三列34说明在一个实施例中微验证参数(micro-validation)可如何被存储在微验证数据库8中。Table 1 of FIG. 3 illustrates the micro-authentication parameters exemplified in the
对于要求验证的实验室检验,在预处理阶段期间,每个要被验证的检验的一个或多个UDT 200以上述所说明的方式被完成。当用户完成要求验证的那些检验的UDT 200时,则认为预配置阶段完成。For laboratory tests requiring validation, one or more UDTs 200 per test to be validated are performed in the manner described above during the preprocessing phase. The pre-configuration phase is considered complete when the user completes the
处理阶段紧跟着预配置阶段,且涉及在数小时、天或周期间对临床培养物的生命周期检验。培养物的处理开始于医生确定培养物需要从患者获取。培养物被从患者获取且被交付到微生物学实验室。在确定培养物适合于身体部位时,如传统地,实验室将此培养物登记到实验室信息系统(LIS)。The processing phase follows the preconfiguration phase and involves life-cycle testing of clinical cultures over hours, days or weeks. Processing of cultures begins when a physician determines that cultures need to be obtained from a patient. Cultures are obtained from patients and delivered to a microbiology laboratory. Upon determining that a culture is suitable for a body part, the laboratory registers this culture with a Laboratory Information System (LIS), as traditionally.
贯穿处理阶段始终,实验室技师执行检验且记录与在考虑当中的培养物有关的结果。为了完成涉及到培养物生命周期检验的必要操作,技师经由用户接口,在此被称为用于处理与实验室检验和结果有关的信息的“工作卡”,与本发明的系统进行接口。Throughout the processing phase, laboratory technicians perform assays and record results pertaining to the culture under consideration. In order to complete the necessary operations related to culture life cycle testing, technicians interface with the system of the present invention via a user interface, referred to herein as a "job card" for processing information related to laboratory tests and results.
图4是所谓的“工作卡”400的一个实施例的显示图像窗口,在处理阶段开始之时所述“工作卡”400被技师调用在工作屏上。FIG. 4 is a display image window of one embodiment of a so-called "job card" 400 that is invoked by a technician on a work screen at the beginning of a processing session.
作为实例,响应于技师对患者血培养物的调用,图4的微工作卡400被示于技师。要理解到:“血培养物”类型(C BLD)411的工作卡表示技师可选择要调用的宽范围培养物类型之一。由技师可调用的其它培养物类型可包括,例如伤口培养物,唾液培养物、尿液培养物等。As an example,
工作卡400是贯穿培养物的检验生命周期始终由实验室候补技师所使用的显示用户接口,当检验结果发生时其允许技师输入、显示、复查、接收和拒绝检验结果。The
工作卡400被分成三个区域,第一(上部)区域402包括标题域411,“C BLD(PRELIM)”及各种患者人口统计,如姓名413-“Dillow,Raliegh”,性别415-“M”,年龄417-“42”,主治医生419-“UNKOWNDOCTOR”。标题域411,例如“C BLD(PRELIM)”将工作卡400标识为工作卡的血培养物类型。The
工作卡400的第二(中间)区域404被标明“Direct Exam”且表示用于显示可直接在标本培养物上执行的检验的区域。在本实例中,项目行412在标题“Test ID”下示出MEDIA及在标题“Rslt”下示出PERFORMED。MEDIA检验是用户定义的检验,其自动地是血培养物组检验的一部分。要注意到一些用户并不对这个检验加以定义。在的确对MEDIA检验加以定义的用户当中,出于包括审查,调查表,系统和内部原因等任何数量的原因,大多数用户使检验自动地带有“PERFORMED”状态的结果。作为选择地,用户可以手动输入MEDIA检验的结果。通过在“Rslt”域看到结果,例如PERFORMED,结合被覆盖日期/时间域418的项目,例如“09/26/2003”,向实验室技师提供血培养物已经被孵育且生命周期检验已经开始的指示。在第二区域404中还示出的是“Culture Tech Note”域421,其用于通过使用工作卡400可在实验室人员当中被共享的非报告信息。A second (middle)
工作卡400的第三(下部)区域406被标明“Culture Workshop”且表示工作卡400这样的区,其用于显示在培养物标本上所执行的非直接检验的状态。在项目行423所指示的“CULT RPT”检验是作为血培养物组检验的一部分而执行的标准检验。每当血培养物类型的工作卡由实验室技师引出时,项目行423被自动地显示。A third (lower)
要理解工作卡400的布局表示代表从中得到布局的传统纸系统的一个实施例。其它布局处于本发明的规划当中。It is to be understood that the layout representation of
图5a是在制备血培养物的正常进展中图4中工作卡400的显示图像窗口。图5a示例在图4中所示的相同数据且附加地包括在工作卡400的“Direct Exam”区域404的项目行512,其指示技师已经执行革兰氏染色剂检验,即“GRAM”,且已经观察到它对应的检验结果,即“MANY GRAM NEGATIVE RODS”。项目行512进一步示出结果已经被输入到系统100内,即在题目“Rslt Sts”下看到“ENT”514。ENT状态指示已经被输入到系统内但还未被发布给医生用于复查的结果。Fig. 5a is a display image window of the
正如在检验领域中的那些在行人员所众所周知,用于执行革兰氏染色剂的准备步骤包括将培养物试样孵育到适当的培养基及显微玻片上,并且将被孵育的培养基放置在孵育器内用于整夜孵育。在孵育周期之后,技师执行Gram Stain检验且将检验结果输入到系统100内。As is well known to those skilled in the art of testing, the preparatory steps for performing Gram stains include incubating culture samples onto appropriate medium and microscopic slides, and placing the incubated medium on In the incubator for overnight incubation. After the incubation period, a technician performs a Gram Stain test and enters the test results into the system 100 .
现在参考图1和5及下面的表II说明输入检验结果的过程。The process of entering test results will now be described with reference to Figures 1 and 5 and Table II below.
首先参考图1,当检验如革兰氏染色剂检验被执行时,结果被输入进系统100。检验经由接口处理器2被输入,所述接口处理器被配置成在贯穿培养物的检验生命周期始终的不同时间阶段接收包括检验结果数据的输入数据。Referring first to FIG. 1 , when a test, such as a Gram stain test, is performed, the results are input into the system 100 . The assay is input via an
表II示例可由图1中接口处理器2所接收的各种类型数据。第一列是对各种数据类型的说明且第二列是对在本发明中所使用的那些数据类型的具体实例的说明。Table II illustrates various types of data that may be received by
表II
通过将实际实验室检验结果9(表II的排3)与要求验证的检验,例如图2中的革兰氏检验及在较后阶段为验证或作废要被验证的检验如革兰氏检验208而进行的进一步被执行的检验的预期检验结果7(表II的排2)进行比较,验证处理器4执行验证处理。出于验证Gram检验208的目的,在图2中示出单个进一步被执行的检验。所示出的进一步被执行的检验是具有其预期结果,即GNRGRP 236的ORG ID检验。当要被验证的检验,如Gram检验208的实际实验室检验结果9(表II的排3)未能与其预期的结果7(表II的排2)匹配时,失败条件被标识。当进一步被执行的实际检验结果15(表II的排6)未能与其预期的检验结果13(表II的排5)匹配时失败条件也被标识。在其中出现失败条件的那些情况下,结果处理器6向用户产生警告消息。By comparing the actual laboratory test results 9 (
预期的结果可以以若干方法被表达。一些常见的表达通过指示,例如培养物对检验化合物有“抵抗性”,或对检验化合物有“敏感性”可被讲述。检验结果另外还可以被简单地表达成具有“阳性的”或“阴性的”检验结果。Expected results can be expressed in several ways. Some common expression can be described by an indication, eg, that the culture is "resistant" to the test compound, or "susceptible" to the test compound. Test results can alternatively be expressed simply as having a "positive" or "negative" test result.
应该理解为预期的结果还可以被表达成数量的定性描述,如在本实例所讲述(GRNGRP=many gram negative rods(许多革兰氏阴性棒)),其中述语“many(许多)”表示对“gram negative rods”数量的定性说明。由本发明所使用的其它定性描述包括,但不局限于“few”(“几个”)、“resistant”(“抵抗性”)、“sensitive”(“敏感”)、“positive”(“阳性的”)和“negative”(“阴性的”)。It should be understood that the expected result can also be expressed as a quantitative qualitative description, as in this example (GRNGRP=many gram negative rods (many gram negative rods)), wherein the predicate "many (many)" means Qualitative illustration of the number of "gram negative rods". Other qualitative descriptions used by the present invention include, but are not limited to, "few" ("several"), "resistant" ("resistant"), "sensitive" ("sensitive"), "positive" ("positive ”) and “negative” (“negative”).
定性描述的一些实例如下。如果要被验证的检验是,例如ORG ID检验且其检验结果是“Klebsiella pnuemoniae”(“肺炎克雷白杆菌”),则确认检验如Ampicilli(AM)(氨卡青霉素)具有“抵抗性”的预期结果。如果ORG ID检验结果是“Staphylococcus aureus”(“金黄色葡萄球菌”),则Vancomycin(VA)(万古霉素)确认检验具有“敏感性”的预期结果。如果ORG ID检验是“Staphylococcus”(“葡萄球菌”),则Catalase确认检验(CAT)(过氧化氢酶确认检验)具有“阳性的”的预期结果。如果ORG ID检验结果是“Streptococcus”(“链球菌”),则Catalase确认检验具有“阴性的”的预期结果。Some examples of qualitative descriptions follow. If the test to be validated is, for example, the ORG ID test and its test result is "Klebsiella pnuemoniae" ("Klebsiella pneumoniae"), confirming that the test such as Ampicilli (AM) (ampicillin) is "resistant" expected outcome. If the ORG ID test result is "Staphylococcus aureus" ("Staphylococcus aureus"), the Vancomycin (VA) (vancomycin) confirmatory test has the expected result of "sensitivity". If the ORG ID test is "Staphylococcus" ("Staphylococcus"), the Catalase Confirmation Test (CAT) (Calase Confirmation Test) has the expected result of "Positive". If the ORG ID test result is "Streptococcus" ("Streptococcus"), the Catalase confirmatory test has the expected result of "negative".
使用定性数量指示符的另一实例将是在这样的情况下,其中Sputum Culture(唾液培养物)被用作具有“Many”革氏兰阴性棒(GNRGRP)的预期结果的确认检验(见图2的218)。再参考图5a,向本发明系统100输入检验标识符及其对应的检验涉及到在图5a中工作卡400的“Add Test”图标516上点击的动作。作为响应,图5b的弹出窗口550被显示给技师。弹出窗口550的区域580列出可由技师添加的用于血培养物实例的各种检验。在本实例中,技师将加亮“GRAM”检验且在“Add”图标582上点击,从而引起弹出窗口550消失且项目行512出现在图5a的工作卡400上。Another example of the use of a qualitative quantity indicator would be in a situation where Sputum Culture (saliva culture) is used as a confirmatory test with an expected result of a "Many" Gram-negative stick (GNRGRP) (see Figure 2 218). Referring again to FIG. 5a, inputting a test identifier and its corresponding test to the system 100 of the present invention involves the action of clicking on the "Add Test" icon 516 of the
通过按下图5a中工作卡400的“Enter Result”图标518,GRAM检验的检验结果,如技师所观察的那样,随后被输入进系统100。作为响应,图5c的弹出窗口570被显示给技师。弹出窗口570包括数量菜单590和说明菜单592,其中数量菜单590列出测量结果数量的菜单,以及说明菜单592列出检验结果说明的菜单。在本实例中,针对GRAMSTAIN检验的“many gram negative rods”结果,技师将从数量菜单590中选择“MANY”且从说明菜单592中选择“GNR”。当在“Add”图标594上点击时,经编码的文本结果“MANY GRAM NEGA TIVERODS”被显示在弹出窗口570的经编码文本结果区域596内,由此给技师提供进一步机会,即在“Apply”图标598上点击之前修改所做出的选择。在“Apply”图标598上点击之后,被输入的检验结果以“MANYGRAM NEGATIVE RODS”出现在图5a中工作卡400的行512上。The test results of the GRAM test, as viewed by the technician, are then entered into the system 100 by pressing the "Enter Result" icon 518 of the
接下来,在检验血培养物试样的正常期间,在较后阶段,技师接收到血培养物试样,其带有在其上生长的有机物。若干微生物学检验被执行且结果经由工作卡400被输入进系统100。在本实例中,在血培养物试样上所执行的生物化学检验导致“Many Staph Aurues”的确定。通过在图5a中工作卡400的“Add/Edit Org”按钮520上进行点击以输入有机物检验结果及有机物标识,技师输入检验结果以用于较后执行的生物化学检验。Next, at a later stage during the normal course of examining a blood culture sample, the technician receives the blood culture sample with organic matter grown thereon. Several microbiological tests are performed and the results are entered into the system 100 via the
图5d是响应于技师在图5a中“Add/Edit Org”按钮520上的点击显示给技师的弹出窗口580。当结果被输入时,它们出现在弹出窗口的右上部分606。有机物数量和标识被输入在区域604,其结果出现在弹出窗口的右下区域608。Figure 5d is a pop-up window 580 displayed to the technician in response to the technician clicking on the "Add/Edit Org"
在示例性的实例中,技师执行两个生物化学检验,催化检验“CAT”及试管凝固酶检验“TUBE”。两个检验结果被技师确定为阳性,导致“Many Staphlococcus Aurues”(“许多金黄色葡萄球菌”)有机物标识。技师在“Apply“图标610上点击以接受此结果。In the illustrative example, a technician performs two biochemical tests, a catalytic test "CAT" and a tube coagulase test "TUBE". Two test results were determined to be positive by the technician, resulting in a "Many Staphlococcus Aurues" ("many Staphlococcus aureus") organism designation. The technician clicks on the "Apply" icon 610 to accept the result.
图6是响应于技师在图5d中的“Apply”图标610上点击的工作卡400的显示图像窗口。显示图像窗口包括区域406中的新项目行416,其表示有着所执行的生物化学检验及有机物的标识等信息。对于本领域中那些普通技术人员所众所周知地是,“Many Staph Aurues”的有机物标识并不是如所预期的Gram Negative Rod类型。所预期的结果是“GNRGRP”236(见图2)。如果非正确的结果被试图发布给医生用于复查,则它将导致验证失败。Figure 6 is a display image window of the
在这一点上有益地是说明各种方法,借此所述各种方法结果可被发布给医生用于复查。总体上,存在三个状态类型:“Enter Status”、“Review Status”和“Release Status”。“Enter Status”定义其中技师将检验结果输入到系统100但并不使结果可用于发言(floor)的情况 “Review Status”定义其中监督员在允许检验结果即将被输入到发言之前对其复查的情况,以及“Release Status”定义其中结果既被输入进系统100又被发布给医生用于复查的情况。上面所说明的状态条件经由四个图标在工作卡400中被实施。It is beneficial at this point to illustrate the various methods whereby the results of the various methods may be released to the physician for review. In general, there are three status types: "Enter Status", "Review Status", and "Release Status". "Enter Status" defines the situation where the technician enters the test results into the system 100 but does not make the results available for the floor "Review Status" defines the situation where the supervisor reviews the test results just before allowing them to be entered on the floor , and "Release Status" defines the situation where results are both entered into the system 100 and released to physicians for review. The status conditions described above are implemented in the
现在参考图6,四个图标,即“Comp/Save”420,“Rel/Save”422,“Rel/Fin/Save”424和“Comp/Fin/Save”426被示在工作卡400的左下侧部分。在此提供各种选项以适应不同的实验室政策和技师用于结果复查的专业技巧水平。Referring now to FIG. 6, four icons, namely "Comp/Save" 420, "Rel/Save" 422, "Rel/Fin/Save" 424 and "Comp/Fin/Save" 426 are shown on the lower left side of the
当检验结果已经被具有适当安全证书的监督员或实验室技师复查时,“Comp/Save”图标420被用来保存所述检验结果。所述复查可在线地或通过使用工作卡400的打印输出而发生。假设继保存即时结果之后附加的检验被执行。换句话说,还一直没有到达培养物检验生命周期的结束。复查之后,检验结果被发布给医生用于复查。The "Comp/Save"
“Rel/Save”图标422被应用于其中实验室技师并不拥有适当的证书且监督复查被委托的情况。假设继保存即时的结果之后附加的检验被执行。换句话说,还一直没有到达培养物检验生命周期的结束。The "Rel/Save" icon 422 is applied to situations where a laboratory technician does not possess the appropriate credentials and a supervisory review is delegated. Assume that additional tests are performed after saving immediate results. In other words, the end of the culture inspection life cycle has not been reached.
“Comp/FinSave”图标424可应用于相同的培养物检验生命周期的结束之时,且包括“Comp/Save”的上面所说明的特点。除了上面提到的特点以外,“Comp/Fin/Save”图标424还将任何更新的/或未保存的数据保存到数据库8。从时间这一点上,培养物的状态从“Preliminary”(“初步的”)变化到“final”(“最终的”)(见图4的“C BLD(PRELIM)”411)。The "Comp/FinSave"
然而,Rel/Fin/Save图标426还可被用来对培养物的生命周期检验加以定案,在这种情况下技师需要执行一附加步骤。具体地,技师被要求手动地执行REVIEW动作(位于工作卡400菜单选项下)。However, the Rel/Fin/
在本实例中,技师试图发布有机物标识检验,即“ORG ID”的实验室检验结果,即,“Many Staph Aureus”。在这种情况下,实际的检验结果并不与预期的检验结果,即“Gram Negative Rod”匹配。因此,试图发布实际的实验室检验结果导致验证失败。In this example, a technician is attempting to issue laboratory test results for Organics Identification Test, ie, "ORG ID", ie, "Many Staph Aureus". In this case, the actual test result did not match the expected test result, "Gram Negative Rod". Therefore, attempts to publish actual laboratory test results resulted in validation failures.
虽然出于示例本发明方面的目的,在正常情况下技师将试图不发布失败的检验,但是假设通过按下“Comp/Save”图标420或“Rel/Save”图标422技师发布实验室检验结果,即“Many Staph Aureus”。Although for the purpose of illustrating aspects of the invention, under normal circumstances a technician will attempt not to issue a failed test, assume that by pressing the "Comp/Save"
图7a是当试图发布失败的结果时被显示给技师的失败验证屏700的显示图像窗口。失败验证屏700提供给技师复查被探测的失败且决定是否忽略此失败并向技师发布此结果的机会。Figure 7a is a display image window of a failure verification screen 700 displayed to a technician when attempting to issue a failed result. The failure verification screen 700 provides an opportunity for the technician to review the detected failure and decide whether to ignore the failure and issue the result to the technician.
独立于本发明的系统,根据预先存在的被结合进实验室信息系统的安全措施,每个技师最初被提供有安全访问状态,其允许技师来执行整个实验室系统内的某些功能。这个安全访问状态的一个方面允许技师忽略其验证安全水平状态被确定为“Informational”(“信息的”)或“Warning”(“报警的”)的任何验证失败。在其中验证安全水平状态是“Failure”的情况下,如果技师的安全状态是“validation”,则技师可忽略所述失败。作为实验室信息系统一部分被结合的授权处理器被用来确定技师的安全状态并且允许或拒绝所述忽略。参考图7a,当技师的状态是“validation”时,技师可以通过按下“Yes”图标716忽略失败。Independent of the system of the present invention, each technician is initially provided with a security access status that allows the technician to perform certain functions within the overall laboratory system, in accordance with pre-existing security measures incorporated into the laboratory information system. One aspect of this security access state allows the technician to ignore any authentication failure whose authentication security level status is determined to be "Informational" ("information") or "Warning" ("warning"). In the case where the verification security level status is "Failure", the technician may ignore the failure if the technician's security status is "validation". An authorization processor incorporated as part of the laboratory information system is used to determine the technician's security status and allow or deny the override. Referring to Figure 7a, when the technician's status is "validation", the technician can ignore the failure by pressing the "Yes" icon 716 .
失败验证屏700被显出包括若干列,所述列包括被命名为“Validation Severity”(“验证严重程度”)702用于说明失败检验的验证失败严重程度的第一列。在所示例的实例中,验证严重程度被示为“FAIL”。如上所陈述,在预处理阶段,经由UDT 200验证严重程度水平被设置。验证严重程度可以被设置成“INFO”,“WARN”或“FAIL”之一。The failed validation screen 700 is displayed to include several columns including a first column named "Validation Severity" ("Validation Severity") 702 for specifying the validation failure severity of the failed check. In the illustrated example, the validation severity is shown as "FAIL". As stated above, in the preprocessing stage, the severity level is set via
失败验证屏700的第二列被命名为“Validated TestID/Result”704,其标识要被验证的检验及其预期的结果。在本实例中,“TestID/Result”是GRAM STAIN检验208(见图2)且预期的结果是许多革兰氏阴性棒“MANY FNR”212(见图2)。The second column of the failed validation screen 700 is named "Validated TestID/Result" 704, which identifies the test to be validated and its expected result. In this example, "TestID/Result" is the GRAM STAIN test 208 (see Figure 2) and the expected result is many Gram negative bars "MANY FNR" 212 (see Figure 2).
失败验证屏700的第三列被命名为“Failed TestID/Result”706,其标识在培养物检验生命周期的较后阶段所执行的检验及其所观察的(实际的)结果。在本实例中,ORG ID检验在较后阶段作为较早被执行的ORG ID检验的确认检验而被执行。如在706中所示,ORG ID的实际检验结果是“MANY STAAUR”。回想起当构建Gram检验208的微验证定义时,图2的ORG ID检验234被包括作为随后要被执行的作为验证或确认检验的检验,如在图2的项目行232a上所示,连同其预期结果,图2的GNRGP 236,其也被示于图7a的第五列710上。在执行ORG ID检验时,其实际的或经观察的结果,即“MANYSTAUUR”706不同于其预期的检验结果GNRGRP236,从而使较早被执行的GRAM STAIN检验208无效。The third column of the failed verification screen 700 is named "Failed TestID/Result" 706, which identifies the test performed at a later stage in the culture test life cycle and its observed (actual) result. In this example, the ORG ID check is performed at a later stage as a confirmation check for the ORG ID check performed earlier. As shown in 706, the actual test result for ORG ID is "MANY STAAUR". Recall that when building the micro-verification definition for the
失败验证屏700的第四列被命名为“User Message”708,其为技师提供这样的指示,即在这种情形下,要被验证的较早被执行的检验/结果704与实际的检验/结果706不匹配。所示出的消息包括用户提示,其建议技师重新确认较早被执行的检验。消息提示还可包括,例如引导技师执行另一预先确定的实验室检验的提示、引导技师重复检验的提示、为用户提供预先确定的消息的提示及标识实际的检验结果及预期的检验结果的提示。The fourth column of the failed verification screen 700 is named "User Message" 708, which provides an indication to the technician that in this case, the earlier performed test/result 704 to be verified differs from the actual test/result The result 706 does not match. The message shown includes a user prompt advising the technician to reconfirm tests that were performed earlier. Message prompts may also include, for example, prompts directing the technician to perform another predetermined laboratory test, prompts directing the technician to repeat the test, prompts to provide the user with predetermined messages, and prompts to identify actual and expected test results .
失败验证屏700的第五列被命名为“Expected Result”710,其标识较后被执行的检验和其相联系的预期结果。在本实例中,较后被执行的“ORG ID”检验的预期结果是“GNRGRP”,即革兰氏阴性棒。The fifth column of the failed verification screen 700 is named "Expected Result" 710, which identifies the last test performed and its associated expected result. In this example, the expected result of the "ORG ID" test performed later is "GNRGRP", the gram-negative rod.
失败验证屏700的第六列被命名为“Requires Comment”712并且显示“Y”(yes)或“N”(no)以向技师提供一快速指示,即为了使验证被忽略,验证是否要求忽略的原因。如果所述列显示“Y”且技师按下YES图标716(并且没有所输入的忽略的原因,见714),则要输入忽略的原因的消息被显示给技师。通过显示给技师其中在验证忽略之前要输入原因的那些情况,这个列可以潜在地节省技师的时间。在本实例中,“N”(no)被示在712,其指示不要求忽略的原因,这样YES图标716可以被按下且验证被忽略而无需在714输入原因。The sixth column of the failed verification screen 700 is named "Requires Comment" 712 and displays "Y" (yes) or "N" (no) to provide a quick indication to the technician whether the verification requires it to be ignored in order for the verification to be ignored s reason. If the column shows "Y" and the technician presses the YES icon 716 (and there is no reason for ignoring entered, see 714), then a message to enter a reason for ignoring is displayed to the technician. This column can potentially save the technician time by showing the technician those instances where a reason is to be entered before verification ignores. In this example, a "N" (no) is shown at 712 , which indicates that no reason for ignoring is required, so the YES icon 716 can be pressed and verification ignored without entering a reason at 714 .
失败验证屏700的第七列被命名为“Reason to Override”714并且提供可能已经被输入的任何“reason for override”的显示。技师有机会提供对忽略验证失败的简洁说明。通过按下图7a中FailureValidation Window(失败验证窗口)左上侧部分处的“Enter Reason ForOverride”图标720,可以输入这个忽略域的文本。“reason foroverride”被结合进可由监督员复查的验证复查记录。下面就与图10相联系对验证复查记录加以定义。The seventh column of the failed verification screen 700 is named "Reason to Override" 714 and provides a display of any "reason for override" that may have been entered. Technicians have the opportunity to provide concise instructions for ignoring verification failures. The text for this ignore field can be entered by pressing the "Enter Reason For Override" icon 720 at the upper left portion of the FailureValidation Window in Figure 7a. "reason foroverride" is incorporated into the verification review log which can be reviewed by supervisors. The verification review record is defined in connection with Figure 10 below.
图7b是响应于技师按下图7a中的“Enter Reason For Override”图标720被示与技师的弹出窗口750的显示图像窗口。弹出窗口750包括用于提供忽略原因的文本项目域752。当在“Add”图标754上点击时,所述文本被包括在图7a的验证窗口的文本域714处。Figure 7b is a display image window of a pop-up window 750 that is shown to the technician in response to the technician pressing the "Enter Reason For Override" icon 720 in Figure 7a. Pop-up window 750 includes a text item field 752 for providing a reason for ignoring. When clicked on the "Add" icon 754, the text is included at the text field 714 of the validation window of Figure 7a.
技师具有这样的选项,即按下图7a的“Yes”图标716以接受(忽略)验证失败并且将较后被执行的检验结果发布给医生,或者按下图7a的“No”图标718并且不将检验结果发布给医生。注意到通过按下“Yes”图标716忽略验证失败导致忽略被包括在可由监督员复查的管理报告中。The technician has the option to press the "Yes" icon 716 of FIG. Release test results to physician. Note that ignoring a verification failure by pressing the "Yes" icon 716 results in the ignoring being included in an administrative report that can be reviewed by a supervisor.
图8是响应于技师按下图7a中失败验证屏处的“No”图标718被示于技师的工作卡400的显示图像窗口。当技师按下“No”图标718并且选择不接受验证失败的检验结果时,技师具有若干选项,其包括再次重新读取革兰氏染色剂,输入革兰氏染色剂的新结果或返回到原始的血培养物且重新开始。选择“No”图标718防止检验结果被发布给医生用于复查。注意到:图8的项目行416(被示出相对于图6中所示的项目行向右卷动)包括在“Rslt Sts”标题下的ENT项目433。这指示所述结果被保存到数据库8但还未被医生用于复查。项目行416进一步示出对有机物所执行的生物化学检验及其联系的结果431。在所示例的实例中,示出对血培养物所执行的两个生物化学检验,即CAT检验和TUBE检验,两者均具有阳性P结果。应该理解为如果用户要求的话,两个生物化学检验,CAT和TUBE还可以按照上面所说明的方式被验证。换句话说,用于验证较早被执行检验的检验可本身由较后被执行的检验所验证。然而,要注意到为了验证任何检验,要求在预处理阶段填充UDT 200。Figure 8 is a display image window shown on the technician's
图9是响应于技师按下图7a中失败验证屏处的“Yes”图标716被示于技师的工作卡400的显示图像窗口。选择“Yes”图标716将检验结果发布给医生。注意到:图8的项目行416(被示出相对于图6中所示的相同行向右卷动)包括在“Rslt Sts”标题下的COMP项目417。COMP项目指示结果已经被保存到数据库且被发布给医生用于复查。Figure 9 is a display image window shown on the technician's
在本实例中,“ORG ID”检验作为正在考虑当中的血培养物的最后验证或确认检验而被加以执行。因此,在执行ORG ID检验并且记录所述结果之后,技师按下“Rel/Fin/Save”图标424以对血培养物的生命周期检验加以定案。In this example, the "ORG ID" test was performed as a final verification or confirmation test for the blood culture under consideration. Therefore, after performing the ORG ID test and recording the results, the technician presses the "Rel/Fin/Save"
图10是复查验证窗口1000的显示图像窗口。复查验证窗口1000可从图9的工作卡400上的下拉清单中获得。在其中培养物具有一个或多个被忽略的验证情况下,监督员具有复查被忽略的失败验证清单的能力并且通过按下“Yes”图标1002具有继续对培养物加以定案的过程的选项或相反通过按下“No”图标1004决定不对所述过程加以定案。FIG. 10 is a display image window of the
虽然本发明已经参考特定的实施例被加以说明,但是应该理解到可以诉诸于许多变化,而不偏离在所附的权利要求中所提出的本发明的实质和范围。技术说明和附图要相应地被视为以示例性的方式且并不旨在限制所附权利要求的范围。Although the invention has been described with reference to particular embodiments, it should be understood that many changes may be resorted to without departing from the spirit and scope of the invention as set forth in the appended claims. The technical description and drawings are to be regarded accordingly by way of illustration and not intended to limit the scope of the appended claims.
Claims (15)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45593403P | 2003-03-19 | 2003-03-19 | |
| US60/455934 | 2003-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1603834A true CN1603834A (en) | 2005-04-06 |
Family
ID=34676539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2004100301359A Pending CN1603834A (en) | 2003-03-19 | 2004-03-19 | System and method for processing related laboratory tests and results |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1603834A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102749466B (en) * | 2007-02-02 | 2014-03-12 | 贝克曼库尔特公司 | System and method for autoverifying laboratory test results |
| CN111351947A (en) * | 2018-12-21 | 2020-06-30 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis equipment and sample test result processing method |
-
2004
- 2004-03-19 CN CNA2004100301359A patent/CN1603834A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102749466B (en) * | 2007-02-02 | 2014-03-12 | 贝克曼库尔特公司 | System and method for autoverifying laboratory test results |
| CN111351947A (en) * | 2018-12-21 | 2020-06-30 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis equipment and sample test result processing method |
| CN111351947B (en) * | 2018-12-21 | 2023-10-20 | 深圳迈瑞生物医疗电子股份有限公司 | Sample analysis equipment and sample test result processing method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040204910A1 (en) | System and method for processing information related to laboratory tests and results | |
| CN115060918B (en) | Modular Assay Reader Device | |
| JP6053749B2 (en) | Image capturing and / or image related parameter recommendation device | |
| CN102749466B (en) | System and method for autoverifying laboratory test results | |
| JP6889520B2 (en) | Diagnostic analyzer related information aggregation method and aggregation system | |
| US20080059241A1 (en) | Interface Between Clinical and Research Information Systems | |
| US10935561B2 (en) | Integrated diagnostic instrument | |
| EP2880577A1 (en) | Systems and methods for designing, developing, and sharing assays | |
| US12300363B2 (en) | Automatically generating rules for lab instruments | |
| CN103299339A (en) | Diagnostic support system | |
| KR102007036B1 (en) | Method to transform clinician order entry | |
| US11017116B2 (en) | Secure integration of diagnostic device data into a web-based interface | |
| Rosenfeld et al. | Radiologist observations of computed tomography (CT) images predict treatment outcome in TB Portals, a real-world database of tuberculosis (TB) cases | |
| US20060278242A1 (en) | Apparatus and methods for medical testing | |
| CN1603834A (en) | System and method for processing related laboratory tests and results | |
| US20070088578A1 (en) | System and method for creating and displaying optional order sets in healthcare environment | |
| Sharma et al. | Is AI really improving the quality of digital diagnosis | |
| CN118609670A (en) | Automated analysis method, device, equipment and storage medium for molecular detection data | |
| JP7282820B2 (en) | Processing data from medical analyzers | |
| JP2001076060A (en) | Clinical examination information processing system | |
| JP2009168731A (en) | Automatic analysis result approval system, automatic analysis system enabling analysis result approval processing, and automatic analysis result approval method | |
| Fredrich et al. | VarWatch—A stand-alone software tool for variant matching | |
| US20070250462A1 (en) | Computerized systems and methods for assessment of genetic test results | |
| CN1845114A (en) | Image management system and image management method | |
| US20160188804A1 (en) | Ambulatory manager |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |